Appointment of Scientific Adviser

RNS Number : 0430P

Angle PLC

03 June 2015

 

For immediate release

3 June 2015

ANGLE plc ("the Company")

APPOINTMENT OF SCIENTIFIC ADVISER

ANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech company, is pleased to announce the appointment of James M. Reuben, PhD, MBA, as a Scientific Advisor to the Company with immediate effect.

Dr Reuben is a Professor in the Department of Hematopathology, Division of Pathology/Lab Medicine at The University of Texas MD Anderson Cancer Center, Houston, Texas. He has conducted extensive research on circulating tumor cell (CTC) subsets, including those with epithelial and mesenchymal phenotypes and their clinical relevance to minimal residual disease in breast cancer.

The University of Texas MD Anderson Cancer Center is one of the world's most respected centres devoted exclusively to cancer patient care, research, education and prevention.  A different part of MD Anderson is already working with ANGLE as a key opinion leader in the field of colorectal cancer. 

Dr Reuben is a leader in translational medicine at MD Anderson and in particular in the area of CTCs and liquid biopsies, a key area of medical development in which he has been working for many years.  Translational medicine is the field involved in taking new research and getting it applied in the treatment of patients.

ANGLE Founder and Chief Executive, Andrew Newland, commented:

"Jim Reuben has exceptional knowledge of circulating tumor cells.  He was one of the leading investigators in the earliest studies on CTCs and has been very actively involved ever since. We are delighted that he has joined ANGLE's Scientific Advisory Board and believe his in-depth knowledge and understanding of CTCs and wide network of contacts in the field will be of great benefit to ANGLE as we drive towards the widespread adoption of the Parsortix system in cancer care."

For further information:

ANGLE plc	01483 685830
Andrew Newland, Chief Executive Ian Griffiths, Finance Director
Cenkos Securities Stephen Keys, Dr Christopher Golden (Nominated adviser) Russell Kerr, Olly Baxendale (Sales)	020 7397 8900
Buchanan Mark Court, Sophie Cowles, Jane Glover	020 7466 5000

For Frequently Used Terms, please see the Company's website on http://www.angleplc.com/the-parsortix-system/glossary/

Notes for editors

About ANGLE plc     www.angleplc.com 

ANGLE is a specialist medtech company commercialising a disruptive platform technology that can capture cells circulating in blood, such as cancer cells, even when they are as rare in number as one cell in one billion blood cells, and harvest the cells for analysis.

ANGLE's cell separation technology is called the Parsortix system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. Parsortix is the subject of granted patents in the United States, China and Australia and three extensive families of patents are being progressed worldwide. The system is based on a microfluidic device that captures cells based on a combination of their size and compressibility. The Parsortix system is established with strong positive evaluations from leading cancer research centres and is working with these cancer centres to demonstrate key applications. Parsortix has a CE Mark for Europe and FDA authorisation is in process for the United States. 

The analysis of the cells that can be harvested from patient blood with ANGLE's Parsortix system has the potential to help deliver personalised cancer care offering profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer.

The global increase in cancer to a 1 in 3 lifetime incidence is set to drive a multi $billion clinical market. The Parsortix system is designed to be compatible with existing major medtech analytical platforms and to act as a companion diagnostic for major pharma in helping to identify patients that will benefit from a particular drug and then monitoring the drug's effectiveness.

Now that the Parsortix system has been developed, ANGLE is focused on its commercialisation in the market. 

ANGLE has established formal collaborations with world-class cancer centres and is working with these cancer centres to demonstrate key applications for its Parsortix non-invasive cancer diagnostic system as a liquid biopsy.  Details are available here http://www.angleplc.com/the-company/collaborators/

As well as cancer, the Parsortix technology has the potential for deployment with several other important cell types in the future.

ANGLE began trading on the AIM market of the London Stock Exchange in March 2004 under the ticker symbol AGL. For further information please visit: www.angleplc.com.

 

END

 

 

MSCPKNDNPBKKCAK